Claims for Patent: 7,766,972

Summary for Patent: 7,766,972

Title:	Synthetic, malleable bone graft substitute material
Abstract:	The invention includes a synthetic bone substitute material suitable for use as a replacement for cancellous bone in a bone graft composition, the material comprising a reticulated framework of interconnecting bioceramic struts defining an interconnecting interstitial void volume, and a solid non-porous composition substantially filling the interstitial void volume and in intimate contact with the reticulated framework, the pore-filling composition comprising calcium sulfate. Calcium triphosphate is a preferred bioceramic material for the reticulated framework.
Inventor(s):	Overby; Robyn J. (Memphis, TN), Schulz; Olaf H. (Arlington, TN), Burgess; Ann V. (Cordova, TN), Haggard; Warren O. (Bartlett, TN), Vincent; Michael (Cordova, TN)
Assignee:	Wright Medical Technology, Inc. (Arlington, TN)
Application Number:	11/772,606
Patent Claims:	1. A synthetic, malleable bone graft substitute composition, comprising: an aqueous mixing solution; calcium sulfate; a plasticizer; demineralized bone matrix; and a plurality of granules comprising a reticulated framework comprising a plurality of interconnecting bioceramic struts and defining an interconnecting interstitial void volume; and a solid, non-porous composition within said interstitial void volume and in intimate contact with said reticulated framework, wherein said solid, non-porous composition comprises calcium sulfate and does not include an interconnecting pore network such that a liquid poured onto one surface of the reticulated framework can not penetrate the calcium sulfate, pass through the framework, and exit the framework via a different surface. 2. The synthetic, malleable bone graft substitute composition of claim 1, wherein the aqueous mixing solution comprises sterile water and, optionally, one or more additives selected from the group consisting of inorganic salts and surface active agents. 3. The synthetic, malleable bone graft substitute composition of claim 1, wherein the calcium sulfate is selected from the group consisting of .alpha.-calcium sulfate hemihydrate, .beta.-calcium sulfate hemihydrate, calcium sulfate dihydrate, and mixtures thereof. 4. The synthetic, malleable bone graft substitute composition of claim 1, wherein the plasticizer is selected from the group consisting of glycerol, vinyl alcohol, stearic acid, hyaluronic acid, cellulose derivatives, and mixtures thereof. 5. The synthetic, malleable bone graft substitute composition of claim 1, wherein the plurality of granules have an average particle size of less than about 8 mm. 6. The synthetic, malleable bone graft substitute composition of claim 1, wherein the reticulated framework defines interstitial openings having a size of about 50 to about 600 .mu.m. 7. The synthetic, malleable bone graft substitute composition of claim 1, wherein the bioceramic struts are formed of a ceramic material selected from the group consisting of alumina, zirconia, calcium phosphate, silica based glass, pyrolytic carbon, and combinations thereof. 8. The synthetic, malleable bone graft substitute composition of claim 1, wherein the bioceramic struts are formed of sintered calcium phosphate. 9. The synthetic, malleable bone graft substitute composition of claim 8, wherein the calcium phosphate is selected from the group consisting of hydroxyapatite, tricalcium phosphate, tetracalcium phosphate, anhydrous dicalcium phosphate, monocalcium phosphate monohydrate, dicalcium phosphate dihydrate, heptacalcium phosphate, octocalcium phosphate, calcium pyrophosphate, oxyapatite, calcium metaphosphate, carbonatoapatite, dahlite, and combinations thereof. 10. The synthetic, malleable bone graft substitute composition of claim 8, wherein the calcium phosphate is selected from the group consisting of .alpha.-tricalcium phosphate, .beta.-tricalcium phosphate, and combinations thereof. 11. The synthetic, malleable bone graft substitute composition of claim 1, wherein the solid, non-porous composition further comprises an accelerant. 12. The synthetic, malleable bone graft substitute composition of claim 11, wherein the accelerant is selected from the group consisting of calcium sulfate dihydrate, sucrose-coated calcium sulfate dihydrate, alkali metal sulfates, and mixtures thereof. 13. The synthetic, malleable bone graft substitute composition of claim 1, wherein the plasticizer is a cellulose derivative selected from the group consisting of methylhydroxypropylcellulose, methylcellulose, ethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, carboxymethylcellulose, cellulose acetate butyrate, and mixtures or salts thereof. 14. The synthetic, malleable bone graft substitute composition of claim 1, wherein the solid, non-porous composition further comprises a biologically active agent. 15. The synthetic, malleable bone graft substitute composition of claim 14, wherein the biologically active agent is selected from the group consisting of growth factors, antibiotics, chemotherapeutic agents, and analgesics. 16. The synthetic, malleable bone graft substitute composition of claim 1, comprising: about 5 to about 50 weight percent aqueous mixing solution; about 5 to about 50 weight percent calcium sulfate; about 0.05 to about 10 weight percent plasticizer; about 2 to about 50 weight percent demineralized bone matrix; and about 5 to about 80 weight percent of the granules. 17. The synthetic, malleable bone graft substitute composition of claim 1, wherein the demineralized bone matrix has an average particle size of about 100 to about 900 .mu.m. 18. The synthetic, malleable bone graft substitute composition of claim 1, wherein the bioceramic struts are formed of a mixture of .alpha.-tricalcium phosphate and .beta.-tricalcium phosphate. 19. The synthetic, malleable bone graft substitute composition of claim 1, wherein the granules comprise about 30 to about 99 percent calcium sulfate by volume and about 1 to about 70 percent bioceramic struts by volume. 20. The synthetic, malleable bone graft substitute composition of claim 1, wherein the solid, non-porous composition fills at least about 95 percent of the interstitial void volume.

Details for Patent 7,766,972

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	ZOSTAVAX	zoster vaccine live	For Injection	125123	05/25/2006		2024-10-22